• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

2.010 -0.050 (-2.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,859,149
Open 2.110
Bid (Size) 2.000 (1,000)
Ask (Size) 2.040 (400)
Prev. Close 2.060
Today's Range 1.950 - 2.150
52wk Range 0.9100 - 2.880
Shares Outstanding 98,384,456
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Fate Therapeutics Appoints Laura Hamill to Board of Directors
Today 8:30 EDT
Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercialization 
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
June 12, 2026
From Equity Insider
Via GlobeNewswire

Performance

YTD
+103.8%
+103.8%
1 Month
+16.2%
+16.2%
3 Month
+73.3%
+73.3%
6 Month
+79.5%
+79.5%
1 Year
+62.1%
+62.1%

More News

Read More
News headline image
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
June 08, 2026
From Biotech Insider
Via GlobeNewswire
News headline image
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
June 04, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
June 01, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
May 21, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
May 20, 2026
Via FinancialNewsMedia
News headline image
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
May 14, 2026
Via FinancialNewsMedia
News headline image
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
May 13, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
May 11, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
May 05, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
May 04, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
April 30, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR
April 16, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
April 09, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
March 18, 2026
From USA News Group
Via GlobeNewswire
Friday's after hours session: top gainers and losers ↗
March 13, 2026
Via Chartmill
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
March 03, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
February 26, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2026
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
January 23, 2026
From Equity Insider
Via GlobeNewswire

Frequently Asked Questions

Is Fate Therapeutics, Inc. - Common Stock publicly traded?
Yes, Fate Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Fate Therapeutics, Inc. - Common Stock trade on?
Fate Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Fate Therapeutics, Inc. - Common Stock?
The ticker symbol for Fate Therapeutics, Inc. - Common Stock is FATE on the Nasdaq Stock Market
What is the current price of Fate Therapeutics, Inc. - Common Stock?
The current price of Fate Therapeutics, Inc. - Common Stock is 2.010
When was Fate Therapeutics, Inc. - Common Stock last traded?
The last trade of Fate Therapeutics, Inc. - Common Stock was at 06/15/26 04:00 PM ET
What is the market capitalization of Fate Therapeutics, Inc. - Common Stock?
The market capitalization of Fate Therapeutics, Inc. - Common Stock is 197.75M
How many shares of Fate Therapeutics, Inc. - Common Stock are outstanding?
Fate Therapeutics, Inc. - Common Stock has 198M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap